Paul W. Ladenson

Paul W. Ladenson

Auto-generated profile, based on publicly available information

Paul W. Ladenson

The Johns Hopkins University School of Medicine, Baltimore, MD 21287-0003, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2000 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
PLPaul W. Ladenson
Paul W. Ladenson
PSPeter A. Singer
Peter A. Singer
KAKenneth B. Ain
Kenneth B. Ain
NBNandalal Bagchi
Nandalal Bagchi
SBS. Thomas Bigos
S. Thomas Bigos
GDGilbert H. Daniels
Gilbert H. Daniels
Research from JAMA Internal Medicine — American Thyroid Association Guidelines for Detection of Thyroid Dysfunction

1 November 1999 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
BHBryan R. Haugen
Bryan R. Haugen
FPFurio Pacini
Furio Pacini
CRChristoph Reiners
Christoph Reiners
MSMartin Schlumberger
Martin Schlumberger
PLPaul W. Ladenson
Paul W. Ladenson
ERE. Chester Ridgway
E. Chester Ridgway
Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after thyroid hormone withdrawal. The objectives of this study were to compare the effect of administered recombinant human TSH with thyroid hormone withdrawal on the results of radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels. Two hundred and twenty-nine adult patients with differentiated thyroid cancer requiring radioiodine WBS were studied. Radioiodine WBS and serum Tg measurements were performed after administration of recombinant human TSH and again after thyroid hormone withdrawal in each patient. Radioiodine whole body scans were concordant between the recombinant TSH-stimulated and thyroid hormone withdrawal phases in 195 of 220 (89%) patients. Of the discordant scans, 8 (4%) had superior scans after recombinant human TSH administration, and 17 (8%) had superior scans after thyroid hormone withdrawal (P = 0.108). Based on a serum Tg level of 2 ng/mL or more, thyroid tissue or cancer was detected during thyroid hormone therapy in 22%, after recombinant human TSH stimulation in 52%, and after thyroid hormone withdrawal in 56% of patients with disease or tissue limited to the thyroid bed and in 80%, 100%, and 100% of patients, respectively, with metastatic disease. A combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation detected thyroid tissue or cancer in 93% of patients with disease or tissue limited to the thyroid bed and 100% of patients with metastatic disease. In conclusion, recombinant human TSH administration is a safe and effective means of stimulating radioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence.

1 May 1999 in Thyroid®
Verified
Journal Article
Closed access
PLPaul W. Ladenson
Paul W. Ladenson
Detection of residual and recurrent thyroid carcinoma requires long-term monitoring of patients with serum thyroglobulin measurement and radioiodine scanning during temporary thyrotropin (TSH) stimulation. Recombinant thyrotropin (rTSH) permits these studies to be performed without the morbidity associated with withdrawal of thyroid hormone therapy. A protocol for rTSH use is proposed, beginning with measurement of serum thyroglobulin during TSH suppression. Patients at significant risk of recurrence with a low initial thyroglobulin level then have rTSH stimulation testing. Patients with positive rTSH-stimulated thyroglobulin concentrations and/or radioiodine scans can then be directed for appropriate therapy. The previously studied 2-dose rTSH protocol with imaging at 48 hours after 131I dosing requires Monday-through-Friday testing in most settings, but new regimens may be established. rTSH-stimulated testing may be less accurate in patients with thyroglobulin autoantibodies and those with residual normal thyroid tissue, and is generally unnecessary when there is other evidence of residual disease. Physicians should consider patients' pretest probability of disease in deciding whether and how often to perform rTSH-stimulated testing after primary treatment for thyroid carcinoma.